JP2024500870A5 - - Google Patents
Info
- Publication number
- JP2024500870A5 JP2024500870A5 JP2023537915A JP2023537915A JP2024500870A5 JP 2024500870 A5 JP2024500870 A5 JP 2024500870A5 JP 2023537915 A JP2023537915 A JP 2023537915A JP 2023537915 A JP2023537915 A JP 2023537915A JP 2024500870 A5 JP2024500870 A5 JP 2024500870A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- terminus
- protein according
- immunomodulatory fusion
- operably linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127995P | 2020-12-18 | 2020-12-18 | |
| US63/127,995 | 2020-12-18 | ||
| PCT/US2021/064224 WO2022133326A1 (en) | 2020-12-18 | 2021-12-17 | Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500870A JP2024500870A (ja) | 2024-01-10 |
| JP2024500870A5 true JP2024500870A5 (https=) | 2024-10-10 |
Family
ID=82058332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537915A Pending JP2024500870A (ja) | 2020-12-18 | 2021-12-17 | 二官能性線状融合コラーゲン局在化免疫調節分子およびその方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240101630A1 (https=) |
| EP (1) | EP4262840A4 (https=) |
| JP (1) | JP2024500870A (https=) |
| KR (1) | KR20230124633A (https=) |
| CN (1) | CN116887850A (https=) |
| AU (1) | AU2021400761A1 (https=) |
| CA (1) | CA3202397A1 (https=) |
| IL (1) | IL303712A (https=) |
| MX (1) | MX2023007326A (https=) |
| WO (1) | WO2022133326A1 (https=) |
| ZA (1) | ZA202306571B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
| WO2025245169A1 (en) * | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| WO2025255560A1 (en) * | 2024-06-07 | 2025-12-11 | Rush University Medical Center | Intranasal p40 monomer and anti-p40 homodimer mab for type 1 diabetes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007073661A1 (fr) * | 2005-12-26 | 2007-07-05 | Yantai Zhenghai Bio-Technology Co., Ltd. | Matieres de squelette de collagene activees et leurs facteurs speciaux de restauration active fusionnee |
| CA2957717C (en) * | 2014-08-12 | 2021-10-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
| US12084495B2 (en) * | 2016-08-03 | 2024-09-10 | Nextcure, Inc. | Compositions and methods for modulating LAIR signal transduction |
| HUE070957T2 (hu) * | 2017-02-16 | 2025-07-28 | Sonnet Biotherapeutics Inc | Albuminkötõ domén fúziós fehérjék |
| AU2019232729B2 (en) * | 2018-03-05 | 2024-08-08 | The University Of Chicago | Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines |
| US10786438B2 (en) * | 2018-04-27 | 2020-09-29 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| AU2019335014A1 (en) * | 2018-09-05 | 2021-03-25 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CA3117961A1 (en) * | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| WO2020163264A1 (en) * | 2019-02-04 | 2020-08-13 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| WO2020186111A2 (en) * | 2019-03-12 | 2020-09-17 | xCella Biosciences, Inc. | Vista-binding antibodies and uses thereof |
-
2021
- 2021-12-17 US US18/257,177 patent/US20240101630A1/en active Pending
- 2021-12-17 JP JP2023537915A patent/JP2024500870A/ja active Pending
- 2021-12-17 AU AU2021400761A patent/AU2021400761A1/en active Pending
- 2021-12-17 EP EP21907967.0A patent/EP4262840A4/en active Pending
- 2021-12-17 MX MX2023007326A patent/MX2023007326A/es unknown
- 2021-12-17 KR KR1020237024345A patent/KR20230124633A/ko active Pending
- 2021-12-17 CN CN202180093757.8A patent/CN116887850A/zh active Pending
- 2021-12-17 WO PCT/US2021/064224 patent/WO2022133326A1/en not_active Ceased
- 2021-12-17 CA CA3202397A patent/CA3202397A1/en active Pending
- 2021-12-17 IL IL303712A patent/IL303712A/en unknown
-
2023
- 2023-06-26 ZA ZA2023/06571A patent/ZA202306571B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500870A5 (https=) | ||
| JP7550745B2 (ja) | Ｉｌ２アゴニスト | |
| RU2770001C2 (ru) | Терапевтические соединения и способы | |
| TWI706960B (zh) | 能夠結合cd19和cd3的雙特異性雙抗體及其用途 | |
| US20210061911A1 (en) | Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies | |
| KR20210031479A (ko) | Cd137 및 ox40에 결합하는 항체 분자 | |
| US20040146948A1 (en) | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments | |
| IL292708B1 (en) | Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them | |
| CN111741764A (zh) | 使用细胞因子编码rna的治疗 | |
| CN105873607A (zh) | 能够结合cd123和cd3的双特异性单价双抗体及其用途 | |
| WO2015037000A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| RS67712B1 (sr) | Imunomodulatorni proteini varijanti icos liganda i povezane kompozicije i postupci | |
| CN104284680A (zh) | 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物 | |
| CN113795272B (zh) | 涉及car工程化的t细胞和细胞因子的治疗 | |
| ES2966569T3 (es) | Proteínas monoespecíficas y biespecíficas con regulación de puntos de control inmunitario para la terapia del cáncer | |
| CA3188236A1 (en) | Heterologous prime boost vaccine | |
| JP2026027331A (ja) | Ｉｌ２アゴニスト | |
| Shashidharamurthy et al. | Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development | |
| Rohrbach et al. | Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity | |
| WO2018187215A1 (en) | Bispecific 4-1bb agonist molecules | |
| US12005082B2 (en) | Composition and method of use recombinant fusion protein to generate CAR-immune cells | |
| US20250090662A1 (en) | Composition and method of use recombinant fusion protein to generate car-immune cells | |
| WO2026046055A1 (en) | Pharmaceutical compositions and methods for preventing or treating cancers | |
| US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof | |
| RU2832189C2 (ru) | Антигенный рецептор |